Open an account

STERIS

STE · NYSE

$225.18+$3.21 (+1.45%)TodayMarket closed ·
Prev close $221.97

About STE

STERIS Plc engages in the provision of healthcare and life science products and service solutions. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

Employees
17,787
Headquarters
DUBLIN
Listed
Nov 3, 2015
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
steris.com

STE key statistics

Market cap
21.96B
Price-earnings ratio
27.14
Dividend yield
1.13%
Average volume
630.47K
Volume
551.04K
Open price
$223.99
High today
$226.63
Low today
$223.28
52 Week high
$269.44
52 Week low
$195.14

STERIS (STE) at a glance

As of Oct 20, 2026, STERIS (STE) shares are priced at $225.18, giving the company a market cap of 21.96B, a price-to-earnings ratio of 27.14 and a dividend yield of 1.13%.

Today the stock has traded between $223.28 and $226.63. The current price is 0.9% above the day's low and 0.6% below its high.

Volume so far is 551.04K shares, in line with the average of 630.47K shares a day.

Over the past year STERIS has ranged from $195.14 to $269.44, and now sits 40% of the way up that range.

STERIS met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY27 it reported $2.59 per share against an estimate of $2.53.

STE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 3.4% on average.

  1. Q2 FY25: reported $2.14 per share against an estimate of $2.14
  2. Q3 FY25: reported $2.32 per share against an estimate of $2.34
  3. Q4 FY25: reported $2.74 per share against an estimate of $2.62
  4. Q1 FY26: reported $2.34 per share against an estimate of $2.29
  5. Q2 FY26: reported $2.47 per share against an estimate of $2.37
  6. Q3 FY26: reported $2.53 per share against an estimate of $2.56
  7. Q4 FY26: reported $2.83 per share against an estimate of $2.88
  8. Q1 FY27: reported $2.59 per share against an estimate of $2.53

STE news

  • Press releasePRNewswire

    Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)

  • Transcript: Steris Q4 2026 Earnings Conference Call

  • Sweta Killa

    April McClain Delaney Bought Up To 15K Worth of Entegris Stock: Here's What You Should Know

  • Press releaseBusiness Wire

    Teleflex Announces Governance Updates

  • Press releaseBusiness Wire

    METTLER TOLEDO Announces Michael J. Tokich to Join Board of Directors

  • Piero Cingari

    Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks

  • Piero Cingari

    Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

  • Avi Kapoor

    Applovin, Sunrun, Duolingo, Tutor Perini, Installed Building Products And Other Big Stocks Moving Higher On Thursday

Similar companies

Companies in the same industry as STERIS

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.